ATE312087T1 - Zyklische äther vitamin d3 verbindungen, 1alfa(oh) 3-epi-vitamin d3 verbindungen und deren verwendungen - Google Patents

Zyklische äther vitamin d3 verbindungen, 1alfa(oh) 3-epi-vitamin d3 verbindungen und deren verwendungen

Info

Publication number: ATE312087T1
Authority: AT; Austria
Prior art keywords: vitamin; compounds; cyclic ether; epi; 1alfa
Prior art date: 1997-05-16

Application number

AT98922374T

Other languages

English (en)

Inventor

Satyanarayana G Reddy

Original Assignee

Woman & Infants Hospital

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-05-16

Filing date

1998-05-15

Publication date

2005-12-15

1998-05-15 Application filed by Woman & Infants Hospital filed Critical Woman & Infants Hospital

2005-12-15 Application granted granted Critical

2005-12-15 Publication of ATE312087T1 publication Critical patent/ATE312087T1/de

Links

QYSXJUFSXHHAJI-YHJXBONMSA-N (1r,3z)-3-[(2e)-2-[(1r,3as,7ar)-7a-methyl-1-[(2r)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol Chemical class C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@H](O)CCC1=C QYSXJUFSXHHAJI-YHJXBONMSA-N 0.000 title abstract 3
-1 CYCLIC ETHER VITAMIN D3 COMPOUNDS Chemical class 0.000 title abstract 2
QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 abstract 3
150000004292 cyclic ethers Chemical group 0.000 abstract 2
QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 abstract 1
230000015572 biosynthetic process Effects 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
238000006345 epimerization reaction Methods 0.000 abstract 1
238000001727 in vivo Methods 0.000 abstract 1
230000037353 metabolic pathway Effects 0.000 abstract 1
239000002243 precursor Substances 0.000 abstract 1
235000005282 vitamin D3 Nutrition 0.000 abstract 1
239000011647 vitamin D3 Substances 0.000 abstract 1
229940021056 vitamin d3 Drugs 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/32—Oxygen atoms
- C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
- C07D303/14—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by free hydroxyl radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D309/06—Radicals substituted by oxygen atoms

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Physical Education & Sports Medicine (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Obesity (AREA)
Hematology (AREA)
Endocrinology (AREA)
Dermatology (AREA)
Nutrition Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pyrane Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

AT98922374T 1997-05-16 1998-05-15 Zyklische äther vitamin d3 verbindungen, 1alfa(oh) 3-epi-vitamin d3 verbindungen und deren verwendungen ATE312087T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US4669097P	1997-05-16	1997-05-16
PCT/US1998/010062 WO1998051678A1 (en)	1997-05-16	1998-05-15	CYCLIC ETHER VITAMIN D3 COMPOUNDS, 1α (OH) 3-EPI-VITAMIN D3 COMPOUNDS AND USES THEREOF

Publications (1)

Publication Number	Publication Date
ATE312087T1 true ATE312087T1 (de)	2005-12-15

Family

ID=21944848

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT98922374T ATE312087T1 (de)	1997-05-16	1998-05-15	Zyklische äther vitamin d3 verbindungen, 1alfa(oh) 3-epi-vitamin d3 verbindungen und deren verwendungen

Country Status (8)

Country	Link
US (5)	US6100294A (de)
EP (1)	EP0981523B1 (de)
JP (1)	JP2002505668A (de)
AT (1)	ATE312087T1 (de)
AU (1)	AU743514B2 (de)
CA (1)	CA2289209C (de)
DE (1)	DE69832699T2 (de)
WO (1)	WO1998051678A1 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19619036A1 (de) *	1996-04-30	1997-11-13	Schering Ag	Neue Vitamin D-Derivate mit carbo- oder heterocyclischen Substituenten an C-25, Verfahren zu ihrer Herstellung und die Verwendung zur Herstellung von Arzneimitteln
DE69832699T2 (de)	1997-05-16	2006-08-24	Woman & Infants Hospital	Zyklische äther vitamin d3 verbindungen, 1alfa(oh) 3-epi-vitamin d3 verbindungen und deren verwendungen
WO1998051663A2 (en) *	1997-05-16	1998-11-19	F. Hoffmann-La Roche Ag	3-epi compounds of vitamin d3 and uses thereof
JP4219553B2 (ja) *	1997-09-08	2009-02-04	エフ．ホフマン−ラロシュアーゲー	１，３−ジヒドロキシ−２０，２０−ジアルキル−ビタミンｄ３類似体
US6531459B1 (en) *	1997-12-17	2003-03-11	Schering Aktiengesellschaft	Vitamin D derivatives with phosphorus atoms in the side chains
EP1172442A4 (de) *	1999-04-14	2004-10-13	Mercian Corp	Vitamin d-derivate und verfahren zur herstellung derselben
CN1173703C (zh) *	1999-04-23	2004-11-03	里奥药物制品有限公司	药物组合物
US6479474B2 (en)	1999-07-08	2002-11-12	Wisconsin Alumni Research Foundation	Dietary calcium as a supplement to vitamin D compound treatment of multiple sclerosis
JP2003516386A (ja) *	1999-12-02	2003-05-13	ザ・ペン・ステート・リサーチ・ファンデーション	ビタミンｄ化合物での炎症性腸疾患の治療
WO2001040177A2 (en)	1999-12-02	2001-06-07	Women And Infants Hospital	Esters of vitamin d3 and uses thereof
US6989377B2 (en)	1999-12-21	2006-01-24	Wisconsin Alumni Research Foundation	Treating vitamin D responsive diseases
US6358939B1 (en)	1999-12-21	2002-03-19	Northern Lights Pharmaceuticals, Llc	Use of biologically active vitamin D compounds for the prevention and treatment of inflammatory bowel disease
EP1270556A4 (de) *	2000-03-30	2005-01-12	Teijin Ltd	Vitamin d intermediate und verfahren zu deren herstellung
US20020137731A1 (en)	2000-05-30	2002-09-26	Gewirtz David A.	Combination of radiation and vitamin D3 analogs for the treatment of cancer
CN100469764C (zh) *	2000-06-15	2009-03-18	中外制药株式会社	维生素d衍生物
US20040030167A1 (en) *	2000-08-08	2004-02-12	Hiroaki Takayama	3-Methyl-20-epi-vitamin d derivatives
AU2002246497A1 (en) *	2000-09-26	2002-07-30	Ganado Research, L.L.C.	Composition and method to increase calcium levels in animals
US20050113348A1 (en) *	2003-06-12	2005-05-26	Yanchun Li	Vitamin D and vitamin D analogs or derivatives as new anti-hypertensive agents
US20060171983A1 (en) *	2003-07-30	2006-08-03	Jin Tian	Use of Vitamin D receptor activators or Vitamin D analogs to treat cardiovascular disease
US20050209203A1 (en) *	2003-07-30	2005-09-22	Jin Tian	Use of vitamin Ds or vitamin D analogs to treat cardiovascular disease
US20050192255A1 (en) *	2003-07-30	2005-09-01	Jin Tian	Use of Vitamin Ds or Vitamin D analogs to treat cardiovascular disease
WO2005027928A1 (en) *	2003-09-19	2005-03-31	Pfizer Products Inc.	2-alkylidene-19-nor-vit amin d derivatives for the treatment of hypocalcemic tetany or hyproparathyroidism
BRPI0404050A (pt) *	2003-09-24	2005-06-14	Bioxell Spa	Uso de um composto ou de um seu sal ou éster farmaceuticamente aceitável, formulação farmacêutica, formulação acondicionada, composto, e, método para prevenir e/ou tratar hiperplasia benigna da próstata em pacientes em necessidade de tal prevenção ou tratamento
EP1714656B8 (de) *	2004-02-06	2017-09-20	Chugai Seiyaku Kabushiki Kaisha	Ed-71-präparat
US20080039434A1 (en)	2004-03-01	2008-02-14	Bioxell S. P.A.	Treatment of Interstitial Cystitis with Vitamin D Compounds
WO2005101022A2 (en) *	2004-04-15	2005-10-27	Bayer Healthcare Ag	Diagnostics and therapeutics for diseases associated with vitamin d (1,25-dihydroxyvitamin d3) receptor 1 (vdr1)
CA2580962A1 (en) *	2004-09-24	2006-04-06	Bioxell S.P.A.	20-cycloalkyl,26,27-alkyl/haloalkyl vitamin d3 compounds and methods of use thereof
CA2586679A1 (en)	2004-11-12	2006-05-18	Bioxell Spa	Combined use of vitamin d derivatives and anti-proliferative agents for treating bladder cancer
US20080069814A1 (en) *	2005-01-05	2008-03-20	Novacea, Inc.	Prevention of Thrombotic Disorders with Active Vitamin D Compounds or Mimics Thereof
AU2006226297A1 (en) *	2005-03-23	2006-09-28	Bioxell Spa	Use of vitamin D compounds to treat endometriosis
AU2006239883A1 (en) *	2005-04-22	2006-11-02	Novacea, Inc.	Treatment, prevention and amelioration of pulmonary disorders associated with chemotherapy or radiotherapy with active vitamin D compounds or mimics thereof
EP1777220A1 (de) *	2005-09-28	2007-04-25	Centre National de la Recherche Scientifique	Vitamin D-Derivate mit Vitamin D nuklear Rezeptor Aktivität, deren Herstellung und deren Verwendung
WO2008131267A2 (en) *	2007-04-18	2008-10-30	Johns Hopkins University	Low calcemic, highly antiproliferative, analogs of calcitriol
WO2009115398A1 (en) *	2008-03-18	2009-09-24	INSERM (Institut National de la Santé et de la Recherche Médicale)	Vitamin d compounds for the treatment of biliary diseases
WO2009153782A1 (en)	2008-06-17	2009-12-23	Ben Gurion University Of The Negev R&D Authority	Substituted cyclohexylidene-ethylidene-octahydro-indene compounds
ES2331289B2 (es)	2008-06-27	2010-06-25	Universidade De Santiago De Compostela	Compuestos de la vitamina d deuterados.
WO2012151058A1 (en)	2011-05-03	2012-11-08	Wisconsin Alumni Research Foundation	(20s)-24-(p-toluenesulfonyloxy)-25,26,27-trinorvitamin d3 analogs and their uses
US9416102B2 (en) *	2013-01-23	2016-08-16	Wisconsin Alumni Research Foundation	(22E)-2-methylene-22-dehydro-1α,24,25-trihydroxy-19-nor-vitamin D3 analogs
WO2016065052A1 (en)	2014-10-22	2016-04-28	Extend Biosciences, Inc.	Insulin vitamin d conjugates
US9585934B2 (en)	2014-10-22	2017-03-07	Extend Biosciences, Inc.	Therapeutic vitamin D conjugates
GB202016614D0 (en)	2020-10-20	2020-12-02	King S College London	Compounds
WO2022269768A1 (ja) *	2021-06-22	2022-12-29	学校法人神奈川大学	ビタミンｄ３様化合物
US12233115B2 (en)	2022-09-30	2025-02-25	Extend Biosciences, Inc.	Long-acting parathyroid hormone
CN117126089A (zh) *	2023-08-30	2023-11-28	正大制药（青岛）有限公司	一种氟骨化醇25-羟基消除化合物的制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4038272A (en) *	1975-10-20	1977-07-26	Hoffmann-La Roche Inc.	Stereospecific syntheses of 24r,25- and 24s,25-dihydroxycholesterol and alkanoyl derivatives thereof
US4021423A (en) *	1976-03-08	1977-05-03	Hoffmann-La Roche Inc.	Syntheses of 24R,25- and 24S,25-dihydroxycholecalciferol
US4206131A (en) *	1978-06-19	1980-06-03	The Upjohn Company	Compounds and process
US4188345A (en) *	1978-07-26	1980-02-12	Wisconsin Alumni Research Foundation	Fluorovitamin D compounds and processes for their preparation
GB8304441D0 (en) *	1983-02-17	1983-03-23	Ruskin B E S	Beverage dispensing apparatus
US4595776A (en) *	1983-03-21	1986-06-17	Hoffmann-La Roche Inc.	Synthesis of 1α,25-dihydroxyergocalciferol
FR2545824B1 (fr)	1983-05-09	1987-11-20	Wisconsin Alumni Res Found	Derive 1a, 25-dihydroxyles de la vitamine d2 et produits intermediaires pour leur preparation et compositions pharmaceutiques renfermant ces derives
JPS6144860A (ja) *	1984-08-10	1986-03-04	Taisho Pharmaceut Co Ltd	１α．２５−ジヒドロキシ−２６．２７−ジメチルビタミンＤ↓３
US4804502A (en) *	1988-01-20	1989-02-14	Hoffmann-La Roche Inc.	Vitamin D compounds
US5145846A (en) *	1988-01-20	1992-09-08	Hoffmann-La Roche Inc.	Vitamin D3 analogs
US5206229A (en) *	1988-04-21	1993-04-27	Leo Pharmaceutical Products Ltd	Vitamin d analogues
US5206230A (en) *	1991-06-05	1993-04-27	Daikin Industries, Ltd.	Fluorine-containing vitamin D3 analogues and pharmaceutical composition containing the same
US5274142A (en) *	1992-03-12	1993-12-28	The Johns Hopkins University	Vitamin D3 analogues
US5830885A (en) *	1992-03-12	1998-11-03	The Johns Hopkins University	Antiproliferative vitamin D3 hybrids
US5547947A (en) *	1993-03-11	1996-08-20	Hoffmann-La Roche Inc.	Methods of treatment
US5401733A (en) *	1993-10-01	1995-03-28	Hoffmann-La Roche Inc.	Stable and active metabolites of 1,25-dihydroxy-16-ene-cholecalciferol
US5428029A (en) *	1993-11-24	1995-06-27	Hoffmann-La Roche Inc.	Vitamin D3 fluorinated analogs
ZA95906B (en) *	1994-02-07	1996-08-06	Res Developments Foundation	Non-viral vector
WO1995027697A1 (en) *	1994-04-11	1995-10-19	Chugai Seiyaku Kabushiki Kaisha	22-thiavitamin d3 derivative
SG70009A1 (en) *	1996-05-23	2000-01-25	Hoffmann La Roche	Vitamin d3 analogs
NO971934L (no) *	1996-05-23	1997-11-24	Hoffmann La Roche	Flourinerte vitamin D3 -analoger
DE69832699T2 (de) *	1997-05-16	2006-08-24	Woman & Infants Hospital	Zyklische äther vitamin d3 verbindungen, 1alfa(oh) 3-epi-vitamin d3 verbindungen und deren verwendungen

1998
- 1998-05-15 DE DE69832699T patent/DE69832699T2/de not_active Expired - Fee Related
- 1998-05-15 EP EP98922374A patent/EP0981523B1/de not_active Expired - Lifetime
- 1998-05-15 AT AT98922374T patent/ATE312087T1/de not_active IP Right Cessation
- 1998-05-15 CA CA002289209A patent/CA2289209C/en not_active Expired - Fee Related
- 1998-05-15 JP JP54963098A patent/JP2002505668A/ja not_active Ceased
- 1998-05-15 WO PCT/US1998/010062 patent/WO1998051678A1/en not_active Ceased
- 1998-05-15 AU AU74936/98A patent/AU743514B2/en not_active Ceased
- 1998-05-15 US US09/079,942 patent/US6100294A/en not_active Expired - Fee Related
1999
- 1999-09-30 US US09/410,223 patent/US6121312A/en not_active Expired - Fee Related
2000
- 2000-07-17 US US09/617,881 patent/US6479538B1/en not_active Expired - Fee Related
2002
- 2002-07-01 US US10/188,320 patent/US20030125309A1/en not_active Abandoned
2003
- 2003-12-30 US US10/750,570 patent/US20080188548A1/en not_active Abandoned

Also Published As

Publication number	Publication date
AU7493698A (en)	1998-12-08
CA2289209C (en)	2006-07-25
US6479538B1 (en)	2002-11-12
US6121312A (en)	2000-09-19
EP0981523B1 (de)	2005-12-07
EP0981523A1 (de)	2000-03-01
US20080188548A1 (en)	2008-08-07
DE69832699D1 (de)	2006-01-12
AU743514B2 (en)	2002-01-24
DE69832699T2 (de)	2006-08-24
WO1998051678A1 (en)	1998-11-19
US6100294A (en)	2000-08-08
US20030125309A1 (en)	2003-07-03
JP2002505668A (ja)	2002-02-19
CA2289209A1 (en)	1998-11-19

Legal Events

Date	Code	Title	Description
2006-06-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE69832699D1 (de)	2006-01-12	Zyklische äther vitamin d3 verbindungen, 1alfa(oh) 3-epi-vitamin d3 verbindungen und deren verwendungen
BG105564A (en)	2002-01-31	Galantamine-containing composition with controlled release
MY122383A (en)	2006-04-29	Cyclic boroproline compounds
SI1037607T1 (en)	2004-08-31	Novel suppository form comprising an acid-labile active compound
IL133397A0 (en)	2001-04-30	Pharmaceutical compositions for oral administration, comprising an active substance and a cyclodextrin
BG103664A (en)	2000-03-31	Pharmaceutical forms containing ammoxycillin and clavulanate
BG103310A (en)	2000-05-31	Benzonaphthyridins as bronchial therapeutical means
MXPA02000973A (es)	2002-07-30	Benzofurilpiperazinas y benzofurilhomopiperazinas: agonistas de serotonina.
TR200102800T2 (tr)	2002-01-21	Yeni bileşikler.
WO2001021766A8 (en)	2001-05-10	Methods and devices for obtaining non-hematopoietic lineage cells from hematopoietic progenitor cells
ATE218581T1 (de)	2002-06-15	Cyclosporinderivat, dessen herstellung und pharmazeutische zusammensetzung
WO2001045678A3 (de)	2002-04-11	Arzneimittel, verfahren zu dessen herstellung und dessen verwendung
MA24643A1 (fr)	1999-04-01	Tetrahydro-naphtalenes substitues et composes analogues
TR200201638T2 (tr)	2002-11-21	Yeni imidazo[1,3,5]triazinonlar ve kullanımları
EP1072254A4 (de)	2005-01-05	Nahrungsmittel, orale zusammensetzungen und medizinische zusammensetzungn zur verhinderung oder behandlung von periodontosis und verfahren zur verhinderung oder behandlung von periodontosis
DE69924846D1 (de)	2005-05-25	Thyroidhormon-analoga und verfahren zu ihrer herstellung
BG103096A (en)	1999-09-30	Thrombin inhibitors
WO2001040177A3 (en)	2002-03-07	Esters of vitamin d3 and uses thereof
DE69230180D1 (de)	1999-11-25	Neuartige hefestämme zur herstellung von xylitol
MXPA02009380A (es)	2004-08-12	Composicion de tenido que contiene un compuesto de para-aminofenol o para-fenilendiamina sustituido por un radical silanico.
DK0842165T3 (da)	2001-08-06	Thiazolidin-4-carboxylsyrederivater som cytobeskyttende midler
PL327060A1 (en)	1998-11-23	Application of 2-ethylhexyl alpha-cyano-beta,beta-diphemylacrylate to improve stability of cosmetic compositions containing p-methylbenzylibene camphor in combination with a derivative of dibenzoyl methane
WO2001009122A3 (en)	2001-06-28	Serotonergic benzofurans
DE69931807D1 (de)	2006-07-20	Herstellung von ascorbinsäure unter verwendung von hefe
MXPA02012112A (es)	2003-06-06	Composiciones que contienen policarbonato.